Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 6/20 | 0.59 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.59 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HNF4A | P41235 | 1/20 | 0.46 |
| ▸ | BCL2 | P10415 | 2/20 | 0.43 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.43 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.42 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.42 |
| ▸ | KDM6B | O15054 | 2/20 | 0.42 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.42 |
| ▸ | ALKBH3 | Q96Q83 | 1/20 | 0.42 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.42 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.42 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.42 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | KDM4A | O75164 | 1/20 | 0.41 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL258224 | 0.78 | KDM6B (0.59) | PTPN1PTPN2PTPN6TSHRKDM6B | |
| SCHEMBL4951259 | 0.78 | KDM4C (0.56) | PTPN1PTPN2PTPN6TSHRKDM6B | |
| SCHEMBL112902 | 0.77 | PTPN1 (0.65) | PTPN1PTPN2PTPN6TSHRHNF4A | |
| SCHEMBL30612910 | 0.77 | PTPN1 (0.65) | PTPN1PTPN2PTPN6TSHRHNF4A | |
| Bicarbonate SCHEMBL236871 | 0.76 | PTPN1 (0.63) | PTPN1PTPN2PTPN6TSHRHNF4A | |
| SCHEMBL1136950 | 0.76 | BCL2 (0.46) | PTPN1PTPN2PTPN6BCL2BCL2L1 | |
| Bicarbonate SCHEMBL21899873 | 0.76 | PTPN1 (0.63) | PTPN1PTPN2PTPN6TSHRHNF4A | |
| SCHEMBL3714683 | 0.75 | PTPN1 (0.76) | PTPN1PTPN2PTPN6TSHRHNF4A | |
| SCHEMBL5444611 | 0.75 | PTPN1 (1.00) | PTPN1PTPN2PTPN6HNF4ABCL2 | |
| SCHEMBL29236440 | 0.73 | PTPN1 (0.97) | PTPN1PTPN2PTPN6HNF4ABCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101128199-B | Monocyclic heterocycles as kinase inhibitors | BRISTOL MYERS SQUIBB CO | 2013-07-24 | — | — | CN | disclosed |
| US-7989477-B2 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989477-B2 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989477-B2 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-02 | — | — | US | disclosed |
| EP-1737451-B1 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-02-23 | — | — | EP | disclosed |
| EP-1737451-B1 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-02-23 | — | — | EP | disclosed |
| US-20100183606-A1 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-22 | — | — | US | disclosed |
| US-20100183606-A1 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-22 | — | — | US | disclosed |
| US-20100183606-A1 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-22 | — | — | US | disclosed |
| US-7732613-B2 | Met kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-08 | — | — | US | disclosed |
| US-20090054436-A1 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-02-26 | — | — | US | disclosed |
| US-20090054436-A1 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-02-26 | — | — | US | disclosed |
| US-7459562-B2 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-02 | — | — | US | disclosed |
| US-7459562-B2 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-02 | — | — | US | disclosed |
| US-7459562-B2 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-02 | — | — | US | disclosed |
| CN-101128199-A | Monocyclic heterocycles as kinase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2008-02-20 | — | — | CN | disclosed |
| US-20070060613-A1 | Met kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-15 | — | — | US | disclosed |
| EP-1737451-A2 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005117867-A2 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050245530-A1 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054436-A1 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | CDK2, MAP3K19, CDK1 | PTPN1 1175/4885PTPN2 970/4885PTPN6 1172/4885 |
| US-20050245530-A1 | Monocyclic heterocycles as kinase inhibitors | CDK2, MAP3K19, CDK1 | PTPN1 1175/4885PTPN2 970/4885PTPN6 1172/4885 |
| US-20100183606-A1 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | CDK2, MAP3K19, CDK1 | PTPN1 1175/4885PTPN2 970/4885PTPN6 1172/4885 |
| US-20070060613-A1 | Met kinase inhibitors | MET, ERBB2, ABL1 | PTPN1 1285/4885PTPN2 1062/4885PTPN6 1101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.